
Sign up to save your podcasts
Or
The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).
4.8
44 ratings
The editors also review the evidence for safinamide for Parkinson’s disease (http://dtb.bmj.com/content/56/5/54), and discuss the use of bezlotoxumab, a monoclonal antibody licensed for the prevention of recurrence of Clostridium difficile infection in adults who are at high risk of recurrence (http://dtb.bmj.com/content/56/5/57).
83 Listeners
2,083 Listeners
39 Listeners
51 Listeners
94 Listeners
8 Listeners
5 Listeners
3 Listeners
2 Listeners
4 Listeners
9 Listeners
38 Listeners
14 Listeners
1 Listeners
51 Listeners
0 Listeners
6 Listeners
14 Listeners
85 Listeners
3 Listeners
21 Listeners
3 Listeners
26 Listeners
24 Listeners
140 Listeners
50 Listeners
11 Listeners
9 Listeners
21 Listeners
5 Listeners
5 Listeners
97 Listeners